11. ¿Una herramienta viable para monitorizar la respuesta inmediata al tratamiento endovascular de la enfermedad arterial periférica?
Abstract
Realizamos el comentario de un estudio retrospectivo que evalúa el dióxido de carbono como agente de contraste en angiografías de perfusión en pacientes con isquemia arterial crónica en lugar del contraste yodado, que presenta gran nefrotoxicidad. Se analiza la metodología seguida por los autores, el nivel de evidencia detrás del estudio y los posibles sesgos.
We comment on a retrospective study that evaluates carbon dioxide as a contrast agent in perfusion angiography in patients with chronic arterial ischemia instead of iodinated contrast, which is highly nephrotoxic. We analyze the methodology followed by the authors, the level of evidence behind the study and possible biases.
Citas
Hinrichs JB, Murray T, Akin M, Lee M, Brehm MU, Wilhelmi M, Wacker FK, Rodt T. Evaluation of a novel 2D perfusion angiography technique independent of pump injections for assessment of interventional treatment of peripheral vascular disease. Int J Cardiovasc Imaging. 2017 Mar;33(3):295-301. Epub 2016 Oct 26. PMID: 27785678. DOI: https://doi.org/10.1007/s10554-016-1008-8
Fujihara M, Kawasaki D, Shintani Y, Fukunaga M, Nakama T, Koshida R, Higashimori A, Yokoi Y; CO2 Angiography Registry Investigators. Endovascular therapy by CO2 angiography to prevent contrast-induced nephropathy in patients with chronic kidney disease: a prospective multicenter trial of CO2 angiography registry. Catheter Cardiovasc Interv. 2015 Apr;85(5):870-7. doi: 10.1002/ccd.25722. Epub 2014 Nov 21. PMID: 25380326. DOi: https://doi.org/10.1002/ccd.25722
Gupta A, Dosekun AK, Kumar V. Carbon dioxide-angiography for patients with peripheral arterial disease at risk of contrast-induced nephropathy. World J Cardiol. 2020 Feb 26;12(2):76-90. doi: 10.4330/wjc.v12.i2.76. PMID: 32184976; PMCID: PMC7061263. Doi: https://doi.org/10.4330%2Fwjc.v12.i2.76
MPG Journal - Política de privacidad